Supports applications bundling phase 1 and phase 1b/2a clinical trials to streamline early evaluation of novel pharmacological interventions for Alzheimer's disease and related dementias. Focus is on agents engaging non-amyloid/non-tau mechanisms addressing cognitive and neuropsychiatric symptoms across disease stages. Proposals must include go/no-go safety and tolerability milestones gating progression from phase 1 to later clinical stages using the UG3/UH3 phased award mechanism.
Eligible applicants include a wide range of organizations such as academic institutions, nonprofits, for-profit organizations, government entities, tribal organizations, small businesses, and certain non-U.S. entities. Specific eligibility extends to various federally recognized and community-servin
